Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
two contrasting cases of adrenal insufficiency in adults a case report
Original title: “Two contrasting cases of adrenal insufficiency in adults: a case report.”
paget s disease of bone pathogenesis ocular manifestations and therapeutic strategies
Original title: “Paget's disease of bone: pathogenesis, ocular manifestations, and therapeutic strategies.”
long term safety and effectiveness of romiplostim in patients with refractory aplastic anemia a nationwide all case post marketing surveillance study in japan
Original title: “Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan.”
choroidal watershed infarction due to medial posterior ciliary artery occlusion with hemi retinal ischemia a case report
Original title: “Choroidal watershed infarction due to medial posterior ciliary artery occlusion with hemi-retinal ischemia, a case report.”
genetic diagnosis in fetuses with biliary tract system abnormalities a meta analysis and systematic review
Original title: “Genetic diagnosis in fetuses with biliary tract system abnormalities: a meta-analysis and systematic review.”
coxfa4l2 upregulation preserves residual cytochrome c oxidase activity in coxfa4 related leigh like encephalopathy
Original title: “COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy.”
septic polyarthritis caused by neisseria meningitidis a rare presentation in japan
Original title: “Septic Polyarthritis Caused by Neisseria meningitidis: A Rare Presentation in Japan.”
peripheral trigeminal nerve branch lesions ct and mri findings in a pathologically confirmed case series
Original title: “Peripheral trigeminal nerve branch lesions: CT and MRI findings in a pathologically confirmed case series.”
idiopathic multicentric castleman disease presenting as recurrent acute onset demyelinating neuropathy
Original title: “Idiopathic Multicentric Castleman Disease Presenting as Recurrent Acute-Onset Demyelinating Neuropathy.”
real world outcomes of fabry disease in italian excellence centers the ground study
Original title: “Real world outcomes of Fabry disease in Italian excellence centers: the ground study.”
unraveling the immune microenvironment in primary cns lymphoma
Original title: “Unraveling the immune microenvironment in primary CNS lymphoma.”
usp24 dependent stat2 stabilization mediates physiologic and pathologic bone formation
Original title: “USP24-dependent STAT2 stabilization mediates physiologic and pathologic bone formation.”
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
Original title: “Bristol Myers unveils data for one of its next-gen blood cancer drugs”
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
Original title: “Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers”
The Advanced Therapy Medicinal Products Market Trends are gaining momentum as healthcare systems increasingly adopt gene therapies cell based therapies and tissue engineered products for chronic and rare diseases According to industry estimates the sector is projected to grow from ... Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00012921?utm_source=OpenPR&utm_medium=10812 Rising Adoption of Cell and Gene Therapies Cell and gene therapies are emerging as transformative solutions for diseases that previously had limited treatment options. The increasing prevalence of cancer, hemophilia, muscular dystrophy, and rare genetic disorders is encouraging healthcare providers to adopt innovative therapeutic approaches. Gene therapies are particularly gaining attention for their ability to address the root causes of inherited diseases rather than only managing symptoms. CAR-T therapy has also demonstrated significant clinical success in oncology applications. Press release - The Insight Partners - Advanced Therapy Medicinal Products Market Size to Reach US$ 46.11 Billion by 2034, Growing at 14.79% CAGR During 2026-2034 - published on openPR.com Healthcare providers are increasingly integrating genomic testing, biomarker analysis, and AI-driven diagnostics into treatment planning. This trend is creating significant opportunities for manufacturers developing customized therapeutic solutions. AI-enabled drug discovery platforms are also reducing development timelines and improving clinical trial efficiency. North America currently dominates the global landscape due to strong healthcare infrastructure, high research spending, and supportive regulatory frameworks. The United States remains a major contributor, supported by extensive clinical trial activity and growing demand for innovative therapies.
Original title: “Advanced Therapy Medicinal Products Market Size to Reach US$ 46.11 Billion by 2034, Growing at 14.79% CAGR During 2026-2034”
The autoinflammatory condition is associated with mutations in the NOD2 gene and usually affects children younger than 4 years. Fever, large-vessel granulomatous vasculitis, malignant hypertension, and granulomatous inflammation of the kidneys, liver, and lungs are some other clinical manifestations of the disease.2 Besides classical clinical features, noncaseating epithelioid cell and giant cell granulomas in the affected tissues are the hallmark of the disease. ... Treating Blau syndrome is a challenging process. Collaborative efforts among dermatologists, pediatricians, and ophthalmologists are needed for optimum disease management of this multisystem inflammatory condition.3 Although Blau syndrome cannot be cured completely, several treatment strategies can help relieve symptoms associated with the condition. This protein is mainly expressed in macrophages, monocytes, and dendritic cells, playing an important role in innate immune defense against pathogens.4 Mutations in the NOD2 gene cause hyperactivation of nuclear factor–κB, resulting in an autoinflammatory disease with an exuberant response.2 The condition can be diagnosed through family history, clinical features, and noncaseating granulomas. Because mutations in a single gene are responsible for causing the disease, Blau syndrome is usually treated as a monogenic autoinflammatory disease. Treatment mainly focuses on preventing progressive ocular symptoms and resulting vision loss, as well as avoiding joint deformation. Arvesen KB, Herlin T, Larsen DA, et al. Diagnosis and treatment of Blau syndrome/early-onset sarcoidosis, an autoinflammatory granulomatous disease, in an infant. Acta Derm Venereol. 2017;97(1):126-127.
Original title: “Blau Syndrome: A Look Into a Rare Disease Requiring Collaborative Treatment | Dermatology Times”
tert rs10069690 variant is linked to reduced cholangiocarcinoma incidence but adverse prognosis in patients undergoing resection
Original title: “TERT rs10069690 variant is linked to reduced cholangiocarcinoma incidence but adverse prognosis in patients undergoing resection.”
rare case of intracranial histiocytic sarcoma a case report and literature review
Original title: “Rare case of intracranial histiocytic sarcoma: A case report and literature review.”